• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    2/14/22 3:51:29 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    SC 13G/A 1 tm226276d2_sc13ga.htm SC 13G/A Schedule 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO § 240.13d-1(b), (c) AND (d) AND

    AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    (Amendment No. 1)*

     

     

    SQZ Biotechnologies Company

    (Name of Issuer)

    Common Stock, Par Value $0.01 per Share

    (Title of Class of Securities)

    78472W104

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 10806X102

    Page 2 of 17

     

      1.   

    Name of reporting persons

     

    American International Group, Inc.

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Incorporated under the laws of the State of Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,529,272

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,529,272

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,529,272

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

     

     

    CUSIP No. 10806X102

    Page 3 of 17

      

      1.   

    Name of reporting persons

     

    SAFG Retirement Services, Inc.

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,529,272

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,529,272

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,529,272

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

      

     

    CUSIP No. 10806X102

    Page 4 of 17

     

      1.   

    Name of reporting persons

     

    SAFG Capital LLC

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,517,173

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,517,173

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,517,173

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

     

     

    CUSIP No. 10806X102

    Page 5 of 17

      

      1.   

    Name of reporting persons

     

    AIG Fund GP Holdings, LLC

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,517,173

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,517,173

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,517,173

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

     

     

    CUSIP No. 10806X102

    Page 6 of 17

      

      1.   

    Name of reporting persons

     

    AIG DECO Fund I, GP, LLC

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Incorporated under the laws of the State of Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,517,173

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,517,173

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,517,173

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

      

     

    CUSIP No. 10806X102

    Page 7 of 17

     

      1.   

    Name of reporting persons

     

    AIG DECO Fund I, LP

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,517,173

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,517,173

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,517,173

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    9.0%

    12.  

    Type of reporting person

     

    HC

     

     

    CUSIP No. 10806X102

    Page 8 of 17

        

      1.   

    Name of reporting persons

     

    AIG Life Holdings, Inc.

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    12,099

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    12,099

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    12,099

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    0.0%

    12.  

    Type of reporting person

     

    HC

     

     

    CUSIP No. 10806X102

    Page 9 of 17

       

      1.   

    Name of reporting persons

     

    AGC Life Insurance Company

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the State of Missouri

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    12,099

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    12,099

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    12,099

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    0.0%

    12.  

    Type of reporting person

     

    IC

     

     

    CUSIP No. 10806X102

    Page 10 of 17

      

      1.   

    Name of reporting persons

     

    The Variable Annuity Life Insurance Company

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the State of Texas

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    9,812

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    9,812

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    9,812

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    0%

    12.  

    Type of reporting person

     

    IC

     

     

    CUSIP No. 10806X102

    Page 11 of 17

      

      1.   

    Name of reporting persons

     

    American General Life Insurance Company

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the State of Texas

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,287

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,287

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,287

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    0.0%

    12.  

    Type of reporting person

     

    IC

     

     

    CUSIP No. 10806X102

    Page 12 of 17

      

      1.   

    Name of reporting persons

     

    SunAmerica Asset Management, LLC

      2.   

    Check the appropriate box if a member of a group

    (a)  ☐        (b)  ☐

     

      3.   

    SEC use only

     

      4.   

    Citizenship or place of organization

     

    Organized under the laws of the State of Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

       5.    

    Sole voting power

     

    0

       6.   

    Shared voting power

     

    2,287

       7.   

    Sole dispositive power

     

    0

       8.   

    Shared dispositive power

     

    2,287

      9.  

    Aggregate amount beneficially owned by each reporting person

     

    2,287

    10.  

    Check box if the aggregate amount in Row (9) excludes certain shares ☐

     

    11.  

    Percent of class represented by amount in Row (9)

     

    0.0%

    12.  

    Type of reporting person

     

    IA

     

     

    Page 13 of 17

     

    ITEM 1 (a). NAME OF ISSUER:

    SQZ Biotechnologies Company

     

    ITEM 1 (b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

    Arsenal Yards Blvd, Suite 210, Watertown, MA 02472

     

    ITEM 2 (a). NAME OF PERSON(S) FILING:

    American International Group, Inc.

    SAFG Retirement Services, Inc.

    SAFG Capital LLC

    AIG Fund GP Holdings, LLC

    AIG DECO Fund I GP, LLC

    AIG DECO Fund I, LP

    AIG Life Holdings, Inc.

    AGC Life Insurance Company

    The Variable Annuity Life Insurance Company

    American General Life Insurance Company

    SunAmerica Asset Management, LLC

     

    ITEM 2 (b). ADDRESS OF PRINCIPAL BUSINESS OFFICE(S):

    American International Group, Inc.

    1271 Avenue of the Americas, 11th Floor,

    New York, NY 10020

    SAFG Retirement Services, Inc.

    21650 Oxnard Street

    10th Floor

    Woodland Hills, CA 91367

     

    SAFG Capital LLC

    21650 Oxnard Street 10th Floor

    Woodland Hills, CA 91367

     

    AIG Fund GP Holdings, LLC

    28 Liberty Street 46th Floor

    New York, NY 10005-1445

     

    AIG DECO Fund I GP, LLC

    28 Liberty Street 46th Floor

    New York, NY 10005-1445

     

    AIG DECO Fund I, LP

    28 Liberty Street 46th Floor

     New York, NY 10005-1445

     

    AIG Life Holdings, Inc.

    2929 Allen Parkway

    Houston, TX 77019

    AGC Life Insurance Company

    2727-A Allen Parkway

    Houston, TX 77019

     

    The Variable Annuity Life Insurance Company

    2929 Allen Parkway

    Houston, TX 77019

    American General Life Insurance Company

    2727-A Allen Parkway

    Houston, TX 77019

    SunAmerica Asset Management, LLC

    Harborside 5 185 Hudson Street Suite 3300

    Jersey City, NJ 07311

     

    ITEM 2 (c). CITIZENSHIP:

    The information requested hereunder is set forth under Item 4 of the cover pages to this Schedule 13G.

    ITEM 2 (d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2 (e). CUSIP NUMBER:

     

    78472W104

      

     

    Page 14 of 17

      

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b), OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

    American International Group, Inc.:

     

      (g) A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

    SAFG Retirement Services, Inc.:

     

      (g) A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

    SAFG Capital LLC:

     

      (g) A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

     

    AIG Fund GP Holdings, LLC:

     

    (g)A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

     

    AIG DECO Fund I GP, LLC:

     

    (g)A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

     

    AIG DECO Fund I, LP:

     

    (g)A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

    AIG Life Holdings, Inc.:

     

      (g) A parent holding company or control person, in accordance § 240.13d-1(b)(1)(ii)(G)

    AGC Life Insurance Company:

     

      (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)

    The Variable Annuity Life Insurance Company:

     

    (c)Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)

    American General Life Insurance Company:

     

      (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)

    SunAmerica Asset Management, LLC:

     

      (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

     

    ITEM 4. OWNERSHIP.

    (a) through (c). The information requested hereunder is set forth under Items 5 through 9 and Item 11 of the cover pages to this Schedule 13G.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    SunAmerica Asset Management, LLC, an indirect subsidiary of American International Group, Inc. (“AIG”) AIG, shares voting and investment power with respect to all of SunAmerica Series SA Small Cap Index Portfolio’s holdings in SQZ Biotechnologies, Co., which AIG may be deemed to indirectly beneficially own such shares.

     

    The Variable Annuity Life Insurance Company, an indirect subsidiary of AIG, shares voting and investment power with respect to all of VALIC Co I Small Cap Index Fund’s holdings in SQZ Biotechnologies, Co., which AIG may be deemed to indirectly beneficially own such shares.

     

    American General Life Insurance Company is an indirect subsidiary of AIG and a LP in LS Polaris Innovation Fund LP which owns 2,287 shares of SQZ Biotechnologies Co. AIG may be deemed to indirectly beneficially own those shares.

     

    AIG Asset Management (U.S.), LLC an indirect subsidiary of AIG, shares voting and investment power with respect to AIG DECO Fund I, LP’s holdings in SQZ Biotechnologies, Co.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    See Exhibit 1 attached hereto for the information requested hereunder with respect to the relevant subsidiaries of American International Group, Inc.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable.

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

    Not applicable.

      

     

    Page 15 of 17

      

    ITEM 10. CERTIFICATION.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    Page 16 of 17

      

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

      AMERICAN INTERNATIONAL GROUP, INC.
         
      By: /s/ Geoffrey N. Cornell
      Name:   Geoffrey N. Cornell
      Title: Senior Vice President and Chief Investment Officer, Life & Retirement
         
      SAFG RETIREMENT SERVICES, INC.
         
      By: /s/ Christine A. Nixon
      Name: Christine A. Nixon
      Title: Senior Vice President
         
      SAFG Capital LLC
         
      By: /s/ Geoffrey N. Cornell
      Name: Geoffrey N. Cornell
      Title: Director
         
      AIG DECO FUND I, LP
       
      By: AIG DECO Fund I GP, LLC, its General Partner
       
      By: AIG Fund GP Holdings, LLC, its Managing Member
       
      By: SAFG Capital LLC, its Managing Member
       
      By: AIG Asset Management (U.S.), LLC, its investment advisor
       
      By: /s/ Matthew Laermer
      Name: Matthew Laermer
      Title: Managing Director
       
      AIG DECO Fund I GP, LLC
       
      By: AIG Fund GP Holdings, LLC, its Managing Member
       
      By: SAFG Capital LLC, its Managing Member
       
      By: AIG Asset Management (U.S.), LLC, its investment advisor
       
      By: /s/ Matthew Laermer
      Name: Matthew Laermer
      Title: Managing Director
       
      AIG Fund GP Holdings, LLC
       
      By: SAFG Capital LLC, its Managing Member
       
      By: AIG Asset Management (U.S.), LLC, its investment advisor
       
      By: /s/ Matthew Laermer
      Name: Matthew Laermer
      Title: Managing Director
         
      AIG LIFE HOLDINGS, INC.
         
      By: /s/ Christine A. Nixon
      Name: Christine A. Nixon
      Title: Senior Vice President
         
      AGC LIFE INSURANCE COMPANY
         
      By: /s/ Christine A. Nixon
      Name: Christine A. Nixon
      Title: Senior Vice President
         
      THE VARIABLE ANNUITY LIFE INSURANCE COMPANY
         
      By: /s/ Christine A. Nixon
      Name: Christine A. Nixon
      Title: Senior Vice President
         
      AMERICAN GENERAL LIFE INSURANCE COMPANY
         
      By: /s/ Christine A. Nixon
      Name: Christine A. Nixon
      Title: Senior Vice President
         
      SUNAMERICA ASSET MANAGEMENT, LLC
         
      By: /s/ Matthew Hackethal
      Name: Matthew Hackethal
      Title: Vice President, Chief Compliance Officer

      

     

    Page 17 of 17

     

    EXHIBIT INDEX

     

    Exhibit 99.1    Identification and Classification of the Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company
    Exhibit 99.2    Agreement of Joint Filing

     

     

     

    Get the next $SQZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vink Patrick V.J.J.

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:48:26 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Srivastava Sapna

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:47:28 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Schulman Amy W

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:46:40 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/13/24 5:13:06 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/9/24 5:10:57 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/14/23 2:25:08 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    SEC Filings

    See more
    • SEC Form DEFM14A filed by SQZ Biotechnologies Company

      DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/23/24 4:31:01 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PREM14A filed by SQZ Biotechnologies Company

      PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/12/24 8:57:36 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by SQZ Biotechnologies Company

      15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

      1/4/24 4:15:33 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

      Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

      6/15/23 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

      Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

      5/10/23 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

      A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

      3/22/23 4:50:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Financials

    Live finance-specific insights

    See more
    • SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

      Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

      12/9/21 6:10:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

      Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

      12/2/21 6:15:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Leadership Updates

    Live Leadership Updates

    See more
    • SQZ Biotechnologies Announces Leadership Transition

      Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a

      9/6/22 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

      Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,

      7/11/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

      Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan

      5/31/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care